<unk>  is a bispecific factor IXa- and factor X-directed antibody that is FDA approved for the prevention or reduction of bleeding episodes in adult and pediatric patients with hemophilia A (congenital factor VIII deficiency) with factor VIII inhibitors. There is a Black Box Warning for this drug as shown here.  Common adverse reactions include injection site reactions, headache, and arthralgia.
Emicizumab
Natalizumab
Caplacizumab
Ixekizumab
Risankizumab
Tocilizumab
Eculizumab
Mogamulizumab